

UCSF

UC San Francisco Previously Published Works

Title

Recommendations for clinical trial design in acute kidney injury from the 31st acute disease quality initiative consensus conference. A consensus statement.

Permalink

<https://escholarship.org/uc/item/9j0834zj>

Journal

Intensive Care Medicine, 50(9)

Authors

Zarbock, Alexander

Forni, Lui

Koyner, Jay

et al.

Publication Date

2024-09-01

DOI

10.1007/s00134-024-07560-y

Copyright Information

This work is made available under the terms of a Creative Commons Attribution-NonCommercial License, available at <https://creativecommons.org/licenses/by-nc/4.0/>

Peer reviewed

CONFERENCE REPORTS AND EXPERT PANEL



Recommendations for clinical trial design in acute kidney injury from the 31st acute disease quality initiative consensus conference. A consensus statement

Alexander Zarbock^{1,2*} , Lui G. Forni^{3,4}, Jay L. Koyner⁵, Samira Bell⁶, Thiago Reis^{7,8,9}, Melanie Meersch¹, Sean M. Bagshaw¹⁰, Dana Y. Fuhmann^{11,12,13}, Kathleen D. Liu¹⁴, Neesh Pannu¹⁵, Ayse Akcan Arikan¹⁶, Derek C. Angus¹³, D'Arcy Duquette¹⁷, Stuart L. Goldstein¹⁸, Eric Hoste¹⁹, Michael Joannidis²⁰, Niels Jongs²¹, Matthieu Legrand²², Ravindra L. Mehta²³, Patrick T. Murray²⁴, Mitra K. Nadim²⁵, Marlies Ostermann²⁶, John Prowle²⁷, Emily J. See^{28,29,30}, Nicholas M. Selby³¹, Andrew D. Shaw³², Nattachai Srisawat³³, Claudio Ronco^{34,35,36} and John A. Kellum^{12,13}

© 2024 The Author(s)

Abstract

Purpose: Novel interventions for the prevention or treatment of acute kidney injury (AKI) are currently lacking. To facilitate the evaluation and adoption of new treatments, the use of the most appropriate design and endpoints for clinical trials in AKI is critical and yet there is little consensus regarding these issues. We aimed to develop recommendations on endpoints and trial design for studies of AKI prevention and treatment interventions based on existing data and expert consensus.

Methods: At the 31st Acute Disease Quality Initiative (ADQI) meeting, international experts in critical care, nephrology, involving adults and pediatrics, biostatistics and people with lived experience (PWLE) were assembled. We focused on four main areas: (1) patient enrichment strategies, (2) prevention and attenuation studies, (3) treatment studies, and (4) innovative trial designs of studies other than traditional (parallel arm or cluster) randomized controlled trials. Using a modified Delphi process, recommendations and consensus statements were developed based on existing data, with > 90% agreement among panel members required for final adoption.

Results: The panel developed 12 consensus statements for clinical trial endpoints, application of enrichment strategies where appropriate, and inclusion of PWLE to inform trial designs. Innovative trial designs were also considered.

Conclusion: The current lack of specific therapy for prevention or treatment of AKI demands refinement of future clinical trial design. Here we report the consensus findings of the 31st ADQI group meeting which has attempted to address these issues including the use of predictive and prognostic enrichment strategies to enable appropriate patient selection.

Keywords: Clinical trials, Endpoints, AKI, Prevention, Treatment, Enrichment

*Correspondence: zarbock@uni-muenster.de

¹ Department of Anesthesiology, Intensive Care and Pain Medicine, University Hospital of Münster, Albert-Schweitzer Campus 1, Building A1, 48149 Münster, Germany

Full author information is available at the end of the article

Alexander Zarbock and Lui G. Forni have contributed equally and share first authorship.

Introduction

Increased morbidity, mortality, and health care utilization are common among patients with acute kidney injury (AKI) [1, 2]. Defined by changes in serum creatinine and urine output, the term “AKI” describes a variety of pathophysiologic processes and as such, no single intervention to prevent, mitigate, or treat AKI has yet been reported. Despite encouraging preclinical results, trials investigating new therapies to treat AKI have failed to demonstrate efficacy [3]. Such failures likely reflect not only the heterogeneous nature of the syndrome and the complexity of the underlying pathophysiology, but potentially also a lack of appropriate endpoints or adequate and timely identification of patients likely to develop AKI, and /or benefit from the intervention in question. To address these problems, the 31st Acute Disease Quality Initiative (ADQI) was convened to develop a common framework for further research. The group focused on four main areas: (1) patient enrichment strategies, (2) prevention and attenuation studies, (3) treatment studies, and (4) innovative trial designs of studies other than traditional (parallel arm or cluster) randomized controlled trials (RCTs).

Methods

The conference chairs (AZ, LGF, and JAK) were appointed by the ADQI executive committee once a topic was decided upon. The faculties were chosen primarily from experts identified by citations on AKI as compiled by expertscape.com. We were limited in the number of experts who could be invited for logistical reasons and we acknowledge that not all experts in AKI trials were invited or available. This list was further refined and developed to include relevant expertise outside of AKI especially on statistics, hierarchical composites, adaptive trial design, and persons with lived experience. Finally, the conference chairs extended invitations to achieve diversity for sex, career stage, specialty including adult and pediatrics, and country of practice.

The Conference Chairs of the 31st ADQI consensus committee convened a diverse panel of adult and pediatric clinicians, researchers, statisticians, and clinical trialists representing relevant disciplines—critical care medicine, anesthesiology, nephrology, and clinical pharmacology—from Europe, North and South America, Asia, and Australia, to discuss endpoints in clinical trials in AKI. Furthermore, a person with lived experience (PWLE) with severe AKI was included in the faculty (DD). The conference was held over 2.5 days in Stresa, Italy, on October 25–28, 2023. This consensus meeting followed the established ADQI process and used a modified Delphi method to achieve consensus, as previously described (additional information in the electronic

Take-home message

Well designed clinical trials have to be designed and implemented to investigate the efficacy of new interventions. Predictive and prognostic enrichment strategies as well as the selection of primary and secondary endpoints are important components of designing such trials.

supplementary material, ESM) [4, 5]. Each ADQI conference is divided into three phases: pre-conference, conference, and post-conference. In the pre-conference phase, the groups that are assigned to specific topics identify a list of key questions, conduct a literature search, and generate a bibliography of key studies. The conference itself is divided into breakout sessions, where workgroups address the issues in their assigned topic area and plenary sessions, where their findings are presented to the entire faculty, debated, and refined. This approach has led to important practice guidelines with wide acceptance and adoption into clinical practice [6]. Given the nature of the topic, consensus statements were not graded by evidence but instead a vote and approval of the consensus recommendations were undertaken. The Delphi process was continued virtually and by email after the conference, until >90% consensus was achieved. Changes to the statements made after the conference and during manuscript preparation were not substantive. These were subsequently reviewed and approved by all authors.

General statements for AKI trials

Consensus statement 1

We **recommend** that researchers, trialists, funding agencies, industry, and regulatory authorities acknowledge the fundamental importance of the perspectives of PWLE in the design and selection of endpoints in clinical trials evaluating AKI, and that PWLE are involved in the clinical trial process, including data analysis, interpretation, and dissemination (supplementary Table 1).

Clinical trials in AKI aim to improve the care and outcomes that are experienced by, and matter to, patients [7]. PWLE, defined as persons regarded as experts by first-hand experience with a diagnosis or health condition, have seldom been involved in the design of clinical AKI trials. However, there is a strong rationale to include PWLE as partners to inform health research to realize improved outcomes, particularly those that are viewed by PWLE as important [7–9]. (supplementary Fig. 1) PWLE can give experienced examples of what they went physically, emotionally, mentally and spiritually. Quality of care is the physicians’ first priority but quality of life is the patient’s priority. In contrast to critically ill patients without an AKI, patients with a severe AKI often receive treatment with renal replacement therapy, have

an increased risk to develop chronic kidney disease, and have a longer length of stay in the intensive care unit and hospital.

There is a “call to action” and established principles on how PWLE can engage in research [7, 9–12]. Evidence has shown that building meaningful partnerships with PWLE can translate into improved quality and relevance of research [8, 13]. However, to realize the value of PWLE partners, we suggest to fully integrate them into all aspects of the research process [14].

Patient enrichment strategies

Consensus statement 2

We **recommend** that investigators consider enriching patient selection for enrollment in AKI clinical trials given the heterogeneous nature of AKI syndromes.

AKI is complex and multifactorial, with multiple conditions presenting with clinically indistinguishable features [15, 16]. The heterogeneous nature of AKI syndromes refers to the different exposures that may all lead to acute decreases in glomerular filtration rate (GFR), but the underlying mechanisms are quite different (cyclosporin-induced AKI vs septic AKI vs cardiorenal AKI). However, a kidney damage without a loss of function is also associated with worse outcome. Heterogeneity in AKI development and clinical course stems from numerous factors including susceptibility, underlying comorbidities, severity of acute illness, presence of extra-renal organ failures, and the type and severity of the insult leading to AKI. Patient baseline variability, including known and unknown differences in chronic and acute characteristics, can drive differential responses to different interventions and will contribute to the heterogeneity of treatment effects observed in clinical trials.

Several approaches can be considered to minimize baseline variability in clinical trials. These include stratified randomization to balance key known or clinically apparent baseline characteristics (e.g., chronic kidney disease [CKD]), use of standardized protocols to minimize process of care variability, selection of a particular clinical setting to focus on a homogenous type of insult (e.g., post-cardiopulmonary bypass), or use of improved diagnostics (e.g., biomarkers) to better identify patient subtypes. Application of prognostic and predictive enrichment strategies (supplementary Table 2) would be expected to identify patients most likely to develop an outcome of interest and respond to an intervention. Precise differential diagnosis may contribute to trial efficiency by selecting patients with traits more likely to favorably respond to candidate

therapies. Implementation of enrichment strategies in AKI could enable identification of the right patients for discrete prevention, treatment, and kidney rehabilitation interventions.

Consensus statement 3

We **recommend** that prognostic enrichment be considered to identify patients who have a greater likelihood of meeting a defined primary endpoint and/or outcome while minimizing the competing risks of undesired endpoints/outcomes.

Prognostic enrichment using various tools can provide an estimate for the risk of an endpoint and help ensure enrollment of ideal patients [17–19] (supplementary Fig. 2). This reduces inclusion of high-risk patients destined to meet a given endpoint regardless of the intervention being tested and conversely prevents enrolling low risk patients who are unlikely to meet the endpoint [18, 20, 21]. Not all risks are modifiable and no risk score/biomarkers are perfect, so caution should be taken to ensure that the correct tools for prognostic enrichment are employed. While older AKI risk scores were static, measuring time-fixed AKI susceptibility, increasingly, new risk scores are dynamic and may employ real-time data allowing for changes in AKI susceptibility and accounting for multiple exposures with the aim of improving risk stratification [22–25]. Urine and serum biomarkers have been used for prognostic enrichment, pairing biomarkers of tubular damage and/or stress with clinical care bundles to improve patient outcomes [18, 26–28]. While prognostic enrichment seeks to increase the probability of a given endpoint/outcome in a trial, it does limit the generalizability of trial findings to only those meeting the enrichment criteria. In the future, prognostic enrichment may combine biochemical biomarkers with real-time risk scores to optimize clinical trial enrollment, outcomes, and costs.

Consensus statement 4

We **recommend** consideration of predictive enrichment and diagnostic precision strategies to identify patients with shared underlying pathobiology.

Predictive enrichment seeks to increase trial efficiency and reduce sample size by optimizing enrollment of patients who will favorably respond to the candidate intervention. Such an approach can avoid exposure/potential toxicity of patients who are unlikely to benefit from an intervention. Various methods to identify patients who are more likely to respond to a specific intervention exist, including biomarkers or clinical features that identify a specific endotype targeted by the intervention. For example, in catecholamine-resistant vasodilatory shock, measuring renin may help to identify

patients for whom treatment with angiotensin II has a beneficial effect on clinical outcomes [29]. Urine tumor necrosis factor- α and interleukin-9 levels have recently been explored to discriminate acute interstitial nephritis from acute tubular necrosis [30, 31]. Such a strategy could lead to specific interventions including immunosuppressive agents.

Consensus statement 5

Enrichment may not be appropriate for all AKI clinical trials.

Enrichment strategies may not be applicable to all trial designs. Generalizability and trial implementation feasibility are two issues that need to be harmonized. Increasing enrichment by restricting enrollment to unique pathobiology will limit the external validity of the intervention and might require more studies with accompanying increased costs to be performed in different populations. Pragmatic trials that are embedded into clinical settings with minimal exclusion criteria are unlikely to be able to accommodate enrichment strategies that may increase implementation complexity and, therefore, decrease enrollment. However, enrollment of a population in a clinical trial that are unlikely to benefit from an intervention is unlikely to be worthwhile.

Prevention and attenuation studies

Consensus statement 6

We **recommend** that when selecting endpoints for AKI prevention studies, investigators consider trial design and endpoint characteristics including: i) biological plausibility; ii) validity in the target population; iii) practicality; and iv) patient centeredness.

We recommend that when selecting endpoints for AKI prevention studies, investigators consider trial design and endpoint characteristics including: i) biological plausibility; ii) validity in the target population; iii) practicality; and iv) patient centeredness.

Numerous factors should be considered when selecting appropriate endpoints for trials examining prevention or attenuation (interventions after exposure but before clinical manifestation) of AKI with some measure of acute injury, damage, stress, or dysfunction as the primary endpoint (Fig. 1, supplementary Tables 3, 4, and 5) [32, 33]. Moreover, endpoint selection should be appropriate for the trial phase [34]. Surrogate endpoints of kidney injury (e.g., functional, damage or stress biomarkers) may be appropriate for phase 2 trials where they capture the effect of the intervention and allow inference of likely clinical outcomes. However, for phase 3 trials, an internationally accepted consensus definition of AKI (currently based on the

Kidney Disease: Improving Global Outcomes (KDIGO) 2012 criteria) may be preferable [35]. It makes intuitive sense to measure the occurrence of AKI if the goal of an intervention is to prevent it. The severity of AKI chosen as the primary endpoint in phase 3 trials requires consideration regarding tradeoff between statistical power (as gained by including all stages of AKI) and identification of definitive renal injury (as is more likely when only severe AKI is studied). Major adverse kidney events (MAKE) [36, 37] is usually not an appropriate endpoint for prevention trials, because the rate of events is too low, and it may be affected by several factors apart from the AKI event. Safety, cost-effectiveness, patient-centered outcome measures, and resource utilization may also be important outcomes for secondary endpoints in phase 2–3 or as primary endpoints for phase 4 studies [38].

Characteristics of appropriate trial endpoints include biological plausibility, validity, practicality, and patient centeredness. A biologically plausible relationship between AKI and an endpoint is highly desirable, particularly when selecting surrogate outcomes (such as biomarkers) in phase 2 trials. Endpoints must have been validated in the target population, especially when studying unique cohorts including pediatrics, pregnant women, and patients with low muscle mass. The practicality of measuring an endpoint has significant implications for trial conduct and future translation into clinical practice, so consideration should be given to ease measurement and general availability. Endpoints must be linked to patient-centered outcomes, especially in phase 3 trials, to ensure that findings align with, and are clinically meaningful, to either patients or caregivers [39, 40]. Finally, confounding and competing events must also be accounted for when interpreting endpoints. Death, intensive care unit (ICU)/hospital discharge, and continuous renal replacement therapy (CRRT) initiation for non-AKI indications are common competing events in AKI prevention studies that must be considered. Management of such events can be handled in the endpoint selection (e.g., through a composite outcome) or in the analysis phase (e.g., through a competing risk analysis). Hierarchical approaches (e.g. win ratio [41]) may also be suitable for analysis of composite endpoints. This technique has been employed successfully for over a decade in the cardiovascular literature and is gaining acceptance in the kidney disease community as well.

AKI is a significant health concern across the entire pediatric age spectrum, with the potential to impact life-course outcomes, highlighting a great need for early prevention and treatment strategies in children [42, 43]. Given the unique challenges with pediatric trials, including competition for funding with adult studies

Prevention Trials [#]		Treatment Trials	
Endpoints	Clinical Trial Phase	Endpoints	Clinical Trial Phase
<ul style="list-style-type: none"> • Molecular biomarkers of kidney injury • Physiological biomarkers such as urinary oxygen tension • Molecular biomarkers of kidney injury or kidney function • Renal functional reserve (physiological biomarker) 	1 or 2 1 or 2 2 2	<ul style="list-style-type: none"> • Rate of change in GFR • Sustained change in GFR • Change in biomarker values specific for kidney damage • Change in genomic or metabolomic variables • Change in levels of inflammatory mediators • Presence or progression of proteinuria 	2 2 2 2 2 2
<ul style="list-style-type: none"> • Stage of AKI • AKI duration • Transition from AKI to acute kidney disease • Development or worsening of chronic kidney disease based on molecular biomarkers such as albuminuria • Development or worsening of chronic kidney disease based on clinical endpoints such as eGFR (or eGFR slope) or reduction of eGFR by 50% • Development or worsening of chronic kidney disease based on clinical endpoints such as need for dialysis or kidney death 	3 3 3 4 4 4	<ul style="list-style-type: none"> • Major Adverse Kidney Events • Days free of organ support therapies: <ul style="list-style-type: none"> -Renal replacement therapy free days -Invasive mechanical ventilation free days -Intensive care/hospital free and alive days • Death • AKI trajectories • Dialysis • Hospital readmission • eGFR reduction or CKD progression 	3 or 4 3 or 4 3 or 4 3 or 4 3 or 4 3 or 4

Fig. 1 Different endpoints should be used in AKI trials on the bases of the type of intervention (prevention or treatment study) and the clinical trial phase (phase 1, 2, 3, or 4). [#] Endpoints that are used for phase 3 trials may also be used as endpoint in phase 4 trials

and, in many cases, classification as an orphan disease due to relatively lower population numbers, the application of prognostic and predictive enrichment strategies is particularly pertinent in pediatric trials. Innovative trial designs and the continued growth of collaborative multi-national groups are critical to addressing these pediatric study challenges. Importantly, children are a heterogeneous group, ranging from preterm neonates to post-pubertal adolescents [44]. Physiological and developmental characteristics differ significantly from adults, vary from newborns to adolescents and young adults, and are dynamic across longitudinal studies [45]. As children progress through various developmental stages, the same outcome measures may not be appropriate when comparing children of different ages. Notably, evaluating baseline kidney health in pediatric studies presents challenges as these measures change from birth to adulthood. Endpoints such as neurodevelopmental outcomes and growth are germane and should be considered in phase 3 and 4 pediatric trials. In addition, it is important for researchers to recognize the importance of qualitative

outcome measures relevant to the child and caregivers, including the impact of AKI and treatment on quality of life [46].

Consensus statement 7

We **recommend** that when selecting endpoints for AKI prevention studies, investigators consider trial design and endpoint characteristics including: i) biological plausibility; ii) validity in the target population; iii) practicality; and iv) patient centeredness.

Baseline kidney health may be assessed in a variety of ways ranging from clinical history to detailed evaluation of numerous measures of kidney functional capacity and cellular/tissue pathology (Fig. 2) [47]. These methods vary in availability, cost, practicality, and accuracy, representing distinct aspects of kidney health (function vs. extent of underlying renal parenchymal disease) [48]. A basic assumption in AKI studies is that individuals recruited for trials have quantified, stable kidney health before the insult occurred even though measures of premorbid kidney function may be unavailable. In these cases, it may be reasonable to impute baseline kidney function based

Methods for Assessment of Baseline Kidney Health for AKI Prevention Studies




Fig. 2 Kidney health is assessed by clinical evaluation and with biomarkers. The availability and/or practicality of the tools reduce from the top to the base of the pyramid. The complexity and/or the financial burden increase in the same direction. The variables in the two layers at the top apply to primary endpoints in phase 3 trials. Meanwhile, the variables in the two layers at the bottom apply to primary endpoints in phase 2 trials. The Biomarkers, Endpoints, and other Tools (BEST) reference glossary lists four types of biomarkers (ref. 38), which are molecular, physiological, radiographic, and histological. Furthermore, BEST defines a biomarker as a defined characteristic that is measured as an indicator of normal biological processes, pathogenic processes, or responses to an exposure or intervention, including therapeutic interventions. AKI acute kidney injury, ⁵¹Cr-EDTA, chromium-51-labeled ethylenediamine tetra-acetic acid, DMSA technetium-99 m-dimercaptosuccinic acid, DTPA technetium-99 m-diethylenetriaminepentaacetic acid, GFR glomerular filtration rate, MAG3 technetium-99 m-mercaptoacetyltriglycine, MRI magnetic resonance imaging. Source: Acute Disease Quality Initiative 31, www.adqi.org, used with permission

on clinical background as recommended in the KDIGO guideline [35].

Consensus statement 8

For phase 2 prevention trials, we **recommend** that measures of kidney function or damage in the acute phase are used as primary endpoints for AKI prevention studies. For phase 3 trials, we recommend use of AKI (stage) as the primary endpoint.

Phase 2 trials evaluate the efficacy of drugs or devices, in preventing the occurrence of new kidney damage or injury and to determine mechanistic pathways and establish biological plausibility for the interventions. These trials are usually smaller than phase 3 trials. Markers of kidney function may be more sensitive than clinical AKI at indicating whether an intervention affects kidney function. Similarly, measuring kidney damage markers, such as urine sediment, proteinuria, or biomarkers, may allow evaluation whether the intervention mitigates new, or different types of damage in the kidneys [49]. In phase 3 trials, the efficacy and safety of interventions are evaluated in larger patient cohorts. As the goal of these

interventions is to prevent AKI, we recommend a primary endpoint of KDIGO-defined AKI.

Treatment studies

Consensus statement 9

We **recommend** that endpoints for phase 2 trials in AKI be selected to directly inform on efficacy, dose–response, biologic response to the treatment, and safety and ideally, correlate with patient-centered outcomes.

Phase 2 trials serve a key fundamental purpose in the development of treatments for AKI, encompassing evidence of efficacy and dose–response, safety, and feasibility (Fig. 1). The endpoints selected to evaluate efficacy must provide a reliable measure of response to the treatment [50, 51]. This can be qualified as categorical (i.e., no response; favorable response; adverse response) or as continuous (i.e., changes in measures of kidney function, damage or other biological variables). Evidence-informed thresholds for endpoints are necessary to describe but are currently largely uncertain. Ideally, these endpoints

are highly correlated, and even causally correlated, with validated patient-centered endpoints. There is recognition that the trial design may guide the selection of context-specific endpoints for phase 2 trials [23, 52–54]. For example, a phase 2 trial evaluating a novel drug or biologic agent to modify kidney injury in patients with persistent AKI may have endpoints that differ from a phase 2 trial evaluating the implementation of a care process bundle in clusters of patients with persistent AKI.

Consensus statement 10

We **recommend** that feasibility measures be explicitly defined for phase 2 trials and encompass measures of success across domains of recruitment, randomization, protocol fidelity, and endpoint measurement.

A key objective of phase 2 trials is an evaluation of whether the trial is feasible to successfully perform and complete given that phase 2 trials have a fundamental role in the rationale and justification for progression to a phase 3 trial [55]. The pursuit of phase 3 trials based on non-feasible phase 2 trials may ultimately compromise the rigorous evaluation of promising treatments for

AKI. This may result from premature termination, loss of internal validity due to protocol violations (e.g., treatment crossover), and information bias due to missed or incomplete endpoint assessment. There are abundant measures of feasibility that phase 2 trials must consider: randomization features [56–58], enrollment measures, protocol fidelity (e.g., treatment delivery), and endpoint measures (e.g., biologic sampling; ascertainment).

These feasibility measures may be independent of the expected biologic action (or clinical action) of the treatment being evaluated.

Consensus statement 11

We **recommend**, when selecting a composite endpoint including hierarchical composite endpoints (HCE), component selection be context-specific when necessary, evidence-informed, and guided by PWLE.

The main objective for a phase 3 trial of treatment for AKI is to establish the effectiveness of the treatment to modify outcomes that are important to patients or society. Regulatory bodies have accepted the MAKE endpoint as indicative of an intervention that meets the “feels, functions or survives” concept of an effective

Table 1 Definitions for phase 2 trial endpoints

Category	Definition	Examples
Efficacy	The ability of a treatment to produce the intended outcome under controlled conditions	Biomarker signatures AKI trajectory Persistent AKI eGFR (delta) Renal functional reserve
Feasibility	The practicality and potential for successful implementation of a treatment	Patient recruitment Patient and clinician Engagement Protocol compliance Data collection/management
Safety	The potential adverse effects or risks associated with a treatment	Adverse events Adverse drug reactions Risk–benefit assessment

AKI acute kidney injury, eGFR estimated glomerular filtration rate

Table 2 A comparison of composite and hierarchical composite endpoints for AKI treatment trials

	Composite endpoint	Hierarchical composite endpoint
Recognition of clinical priorities	• Generally does not distinguish the relative clinical significance of each component	• Formulates the component endpoint into a hierarchy based on their relative importance
Familiarity	• Well known	• A newer statistical method
Statistical efficiency	• Reduced sample size requirement when compared to testing individual endpoints	• Reduced sample size requirement when compared to testing individual endpoints • Can be extended to account for recurrent events without statistical complexity • Requires the calculation of a win ratio which requires statistical software
Cost	• Reduced costs when compared to testing individual endpoints	• Reduced costs when compared to testing individual endpoints

treatment for AKI. However, achieving success with MAKE has proved difficult and this, in turn, has led to efforts to provide suitable alternatives. The selection of endpoints for phase 3 trials of treatments for AKI have often focused on conventional endpoints with clinical importance and composite endpoints [56, 59] (Table 1). These endpoints may align with the principles of patient-centeredness but have seldom been directly informed by PWLE. Composite endpoints have the recognized advantage of improving trial efficiency but they also have drawbacks (Table 2). Selected composite endpoints can have importance to both PWLE and potentially society as a whole. For example, “organ-support”-free days, ICU-free days or alive and out-of-hospital are composite endpoints that integrate both patient centeredness and resource utilization [60–62]. The increased use of hierarchical composite endpoints (HCE) (e.g., win ratio) represents an innovation that we suggest can be applied to treatment trials in AKI and also be leveraged to integrate outcomes perceived as important to PWLE [41, 63–65]. HCE select a range of endpoints ranked in order of importance (supplementary Fig. 3). Their advantages and disadvantages have been reviewed elsewhere [66]. One disadvantage of the win ratio is that this strategy does not allow for an accurate calculation of the number needed to harm or treat (magnitude of the overall effect). Another limitation is that, although hierarchically ordered, each component of the hierarchical endpoint is weighted the same when using the win ratio, so it could be driven by its least clinically meaningful component. Surrogate measures with correlation to clinically important outcomes can also be integrated into HCE. Innovation in selection of endpoints and in the analytic strategies utilized may further improve and simplify the interpretation of phase 3 trials for PWLE and knowledge users of health research, along with facilitation of clinical adoption [56, 63, 67].

Designs of studies other than traditional randomized clinical trials (RCT)

Consensus statement 12

We **recommend** the use of an innovative clinical trial design when it addresses challenges of AKI that are relevant to the research question, or when it provides one or more advantages over traditional designs. Elements to be considered when designing innovative clinical trials include unit of randomization, design features, and analytic strategy.

For decades, the gold standard for experimental design was the two-arm, parallel group RCT [56, 68]. This design is well suited when there are two alternative approaches to care, and the anticipated benefits are

expected to accrue evenly to all recipients. There are, however, many clinical situations where there may be multiple approaches to care, and benefits may be heterogeneous. In such situations, researchers often reduce the complexity of the clinical problem to a testable question under this design, running the risk of oversimplification. Risks include failing to detect the benefit of a therapy that works differentially in different subsets of patients and failing to determine the optimal manner of delivering a therapy when there are more than two approaches. Given advances in statistical design and software, there are now several robust alternative study design choices that can be chosen to match the complexity of the clinical problem. Adopting this rubric of selecting a trial design that is fit for purpose may well be advantageous in the study of therapies for AKI, especially in late phase and post-approval settings.

The nature of AKI itself poses several challenges for standard 2 arm RCTs of an intervention at a single point in time (supplementary Fig. 3) [69, 70]. Specifically, the timing of disease presentation is heterogeneous as the timing between AKI onset and clinical presentation is often difficult to ascertain. Furthermore, there is no current method to distinguish the course of AKI at the time of initial presentation. Given the window to intervene on AKI may be narrow, the time frame to more precisely define AKI or its characteristics is compressed when considering potential enrollment into trials. This is in contrast to oncology, for example, where it is possible to perform detailed molecular phenotyping over the course of several days to determine participant eligibility. Innovative clinical trial designs may overcome some of these challenges; for example, basket [71] or SMART clinical trials may allow for the testing of one intervention across the spectrum of AKI and acute kidney disease (AKD) (supplementary Table 5).

In addition to the potential benefit of innovative designs on some of the specific challenges faced in clinical trials for AKI, other benefits include increased efficiency, improved feasibility, expanded access/equity, and the ability to test the effect of one or more interventions across the continuum of a disease. For example, a platform design can allow for rapid and more cost-effective testing of an intervention [72]. If the standard of care for AKI changes over time, this can be incorporated into the platform trial (supplementary Table 5). Bayesian analysis, when prior probabilities can be estimated with some degree of confidence, can reduce sample size compared to frequentist analyses.

Innovative clinical trials may randomize patients at the individual or at the population level, e.g., clusters. Clusters can occur at many levels, including the hospital unit, hospital itself, or provider level. Within cluster

RCTs, crossover designs may lead to contamination of the intervention as the clusters cross over repeatedly; the stepped-wedge design avoids this issue yet allows for a cluster to serve as its own internal control. Cluster randomized trials use a pragmatic study design that is increasingly used to evaluate service delivery-type interventions. However, cluster trials with individual recruitment and without concealment of allocation (or blinding of the intervention) are at risk of selection biases. As described in supplementary Table 5, a number of different innovative clinical trial design features can be considered; each has pros and cons that need to be considered vis-à-vis the specific intervention to be tested. Pragmatism is a concept that refers to the utility of interventions in daily clinical practice and is typically applied in the context of process of care interventions or established therapeutics, rather than regulatory trials for novel therapeutics, devices, or diagnostics. The pragmatism of a trial can be evaluated using the PRECIS-2 tool [73]. In contrast to a frequentist framework, where analysis is based on the absolute probability of a result, Bayesian analytic frameworks use pretest probability to inform the likelihood of a result. With rigorously established priors, Bayesian analytic frameworks can reduce the sample size needed for a clinical trial.

Limitations

A limitation that affects all AKI trials is the definition of AKI, because it uses very non-specific markers (serum creatinine and urine output) to define a syndrome that encompasses a broad range of pathophysiological processes. Another limitation is that some of the statements are rather general, and could apply to other forms of critical illness or to good clinical trial design of any sort. In addition, the group mainly focused on processes rather than on goals.

Conclusion

There are many challenges to prevention and treatment trial design in AKI. However, we have highlighted approaches which, if adopted, may allow for use of clinically meaningful and patient-centered approaches which, in turn, will promote trials with a greater potential for finding therapies that prevent or treat AKI effectively.

Supplementary Information

The online version contains supplementary material available at <https://doi.org/10.1007/s00134-024-07560-y>.

Author details

¹ Department of Anesthesiology, Intensive Care and Pain Medicine, University Hospital of Münster, Albert-Schweitzer Campus 1, Building A1, 48149 Münster, Germany. ² Outcomes Research Consortium, Cleveland, OH, USA. ³ Department of Critical Care, Royal Surrey Hospital Foundation Trust, Guildford, Surrey, UK. ⁴ School of Medicine, Kate Granger Building, University of Surrey, Guildford,

Surrey, UK. ⁵ Section of Nephrology, University of Chicago, Chicago, IL, USA. ⁶ Division of Population Health and Genomics, University of Dundee, Dundee, UK. ⁷ Hospital Sírio-Libanês, São Paulo, Brazil. ⁸ Fenix Nephrology, São Paulo, Brazil. ⁹ Laboratory of Molecular Pharmacology, University of Brasília, Brasília, Brazil. ¹⁰ Department of Critical Care Medicine, Faculty of Medicine and Dentistry, University of Alberta and Alberta Health Services, Edmonton, AB, Canada. ¹¹ UPMC Children's Hospital of Pittsburgh, 4401 Penn Avenue, Suite 2000, Pittsburgh, PA 15224, USA. ¹² Center for Critical Care Nephrology, University of Pittsburgh, Pittsburgh, PA, USA. ¹³ Department of Critical Care Medicine, University of Pittsburgh, Pittsburgh, PA, USA. ¹⁴ Departments of Medicine and Anesthesia, University of California, San Francisco, San Francisco, CA, USA. ¹⁵ Department of Medicine, University of Alberta, Edmonton, AB, Canada. ¹⁶ Division of Nephrology and Critical Care Medicine, Department of Pediatric, Baylor College of Medicine, Houston, TX, USA. ¹⁷ Critical Care Strategic Clinical Network, Alberta Health Services, Calgary, Canada. ¹⁸ Division of Nephrology and Hypertension, Cincinnati Children's Hospital Medical Center, Cincinnati, USA. ¹⁹ Intensive Care Unit, Ghent University Hospital, Ghent University, Ghent, Belgium. ²⁰ Division of Intensive Care and Emergency Medicine, Department of Internal Medicine, Medical University Innsbruck, Innsbruck, Austria. ²¹ Department of Clinical Pharmacy and Pharmacology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands. ²² Department of Anesthesia and Perioperative Care, Division of Critical Care Medicine, UCSF, San Francisco, CA, USA. ²³ Department of Medicine, University of California San Diego, La Jolla, San Diego, CA, USA. ²⁴ School of Medicine, University College Dublin, Dublin, Ireland. ²⁵ Division of Nephrology and Hypertension, Department of Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA. ²⁶ Department of Intensive Care, King's College London, Thomas' Hospital, Guy's & St, London, UK. ²⁷ Faculty of Medicine and Dentistry, William Harvey Research Institute, Queen Mary University of London, London, UK. ²⁸ Department of Critical Care, University of Melbourne, Parkville, Australia. ²⁹ Department of Intensive Care, Royal Melbourne Hospital, Melbourne, VIC, Australia. ³⁰ Department of Nephrology, Royal Melbourne Hospital, Melbourne, VIC, Australia. ³¹ Centre for Kidney Research and Innovation, University of Nottingham, Nottingham, UK. ³² Department of Intensive Care and Resuscitation, The Cleveland Clinic, Cleveland, OH, USA. ³³ Division of Nephrology, Department of Medicine, Faculty of Medicine, and Center of Excellence in Critical Care Nephrology, Chulalongkorn University, Bangkok, Thailand. ³⁴ Department of Medicine, University of Padova, Padua, Italy. ³⁵ International Renal Research Institute of Vicenza (IRRV), Vicenza, Italy. ³⁶ Department of Nephrology, San Bortolo Hospital, Vicenza, Italy.

Acknowledgements

The authors wish to acknowledge Gioia Vencato and Annamaria Saccardo, for their help in organizing this ADQI meeting.

Author contributions

All authors made equal contributions to the discussion of the content and researching data for the article. Members of each group contributed equally to writing their sections. LGF, AZ, and JAK combined the workgroup drafts and edited for style and length. All authors reviewed the final manuscript before submission.

Funding

Open Access funding enabled and organized by Projekt DEAL. This conference was kindly supported by unrestricted educational grants from 4TEEN4, AM Pharma, AstraZeneca, Baxter, Bayer, BioPorto, Chugai Pharmaceutical, Mission Therapeutics, Novartis, Ocelot Bio, and Spingotec.

Declarations

Conflicts of interest

Grants from industry were used to pay for travel, accommodations, conference venue, website, and administrative costs. No participants received payments for their participation. Industry representatives were permitted to attend the meeting as observers—they did not participate in any of the voting and were not provided an advanced copy of the manuscript. AZ has received consulting fees from Astute-Biomerieux, Baxter, Bayer, Novartis, Guard Therapeutics, AM Pharma, Paion, Fresenius, research funding from Astute-Biomerieux, Fresenius, Baxter, and speakers fees from Astute-Biomerieux, Fresenius, Baxter; LGF has received research support and lecture fees from Ortho Clinical Diagnostics,

Baxter, Exthera and Biomerieux and consulting fees from La Jolla Pharmaceuticals and Paion; SB has received consultancy fees from AstraZeneca, Bayer and GSK; AAA serves on the scientific advisory board of Seastar and has received research funding from Bioporto, Baxter, and Medtronic; NMS has received consulting fees from GE, AstraZeneca (paid to institution) and speaker fees from Fresenius (paid to institution); SLG has received grant support from BioPorto Diagnostics, Baxter, NuWellis, ExThera Medical, SeaStar Medical, Roche, Otsuka and consulting fees from BioPorto Diagnostics, Baxter, NuWellis, SeaStar Medical, Talphera, Otsuka, Calcimedica, Fresenius. He has ownership interest in MediBeacon Inc. and receives licensing revenues from RAIDAR Health; NS has received research funding from Baxter; TR has received consulting fees for Baxter, bioMérieux, Eurofarma, George Clinical, Medcorp and lectures fees for Alexion, AstraZeneca, B Braun, Baxter, bioMérieux, Boehringer Ingelheim, Contatti Medical (CytoSorbents), Eurofarma, Jafron, Lifepharm, Medcorp, Nova Biomedical, and Nipro; SMB has received fees for scientific advisory from Baxter, bioMérieux, BioPorto, Novartis, Sea Star Medical, and SphingoTec.; ADS has received consulting fees from AM Pharma, Novartis, Alexion, CalciMedica, Fresenius and Retia Medical; JLK has received consulting fees from Astute-Biomerieux, Bioport, Baxter, Novartis, Guard Therapeutics and SeaStar and research funding from Astute-Biomerieux, Fresenius; PTM serves as a scientific advisor for AM-Pharma, Novartis, Alexion, Bioport, CalciMedica, and Renibus Therapeutics; MJ has received honoraria or research support from Baxter Healthcare Corp, AM-Pharma, CLS Behring, Fresenius, Takeda, Biomerieux and Novartis; RLM has received consulting fees from Alexion, Baxter, Fresenius, AM Pharma, Sphingotec, Novartis, Guard therapeutics, SeaStar; JP has received consulting fees from Mission Therapeutics, Paion, Baxter, Novartis, bioMérieux, Nephrolyx, Jafron, Nikkiso and lecture fees from Baxter and Nikkiso; CR is a consultant for ASAHI, Baxter, GE, Jafron, and Medtronic and has received speaker fees from Astute, bioMérieux, B Braun, CytoSorbents, ESTOR, FMC, and Toray; JAK has received consulting fees from Alexion, Astellas, Astute-Biomerieux, Chugai Pharma, Mitsubishi Tenabe, Novartis, 3iveLabs and is a full-time employee of Spectral Medical. The remaining authors declare no competing interests.

Open Access

This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by-nc/4.0/>.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Received: 28 April 2024 Accepted: 10 July 2024

Published: 8 August 2024

References

- Hoste EAJ, Kellum JA, Selby NM, Zarbock A, Palevsky PM, Bagshaw SM, Goldstein SL, Cerda J, Chawla LS (2018) Global epidemiology and outcomes of acute kidney injury. *Nat Rev Nephrol* 14:607–625
- Zarbock A, Koyner JL, Hoste EAJ, Kellum JA (2018) Update on perioperative acute kidney injury. *Anesth Analg* 127:1236–1245
- Pickkers P, Murray PT, Ostermann M (2022) New drugs for acute kidney injury. *Intensive Care Med*. <https://doi.org/10.1007/s00134-022-06859-y>
- Kellum JA, Bellomo R, Ronco C (2008) Acute Dialysis Quality Initiative (ADQI): methodology. *Int J Artif Organs* 31:90–93
- Nadim MK, Furni LG, Bihorac A, Hobson C, Koyner JL, Shaw A, Arnaoutakis GJ, Ding X, Engelman DT, Gasparovic H, Gasparovic V, Herzog CA, Kashani K, Katz N, Liu KD, Mehta RL, Ostermann M, Pannu N, Pickkers P, Price S, Ricci Z, Rich JB, Sajja LR, Weaver FA, Zarbock A, Ronco C, Kellum JA (2018) Cardiac and vascular surgery-associated acute kidney injury: the 20th international consensus conference of the ADQI (Acute Disease Quality Initiative) group. *J Am Heart Assoc*. <https://doi.org/10.1161/JAHA.118.008834>
- Kellum JA (2020) Impact of Consensus Papers versus Randomized Trials in Critical Care Nephrology. *Blood Purif* 49:708–712
- Research ClfH (2014) Strategy for Patient-Oriented Research Patient Engagement Framework. In: Editor (ed)^(eds) Book Strategy for Patient-Oriented Research Patient Engagement Framework. CIHR, City, pp.
- Kimmel PL, Jefferson N, Norton JM, Star RA (2019) How Community Engagement Is Enhancing NIDDK Research. *Clin J Am Soc Nephrol* 14:768–770
- Research NlfHaC (2021) Different experiences: A framework for considering who might be involved in research. In: Editor (ed)^(eds) Book Different experiences: A framework for considering who might be involved in research. City, pp.
- Harrison JD, Auerbach AD, Anderson W, Fagan M, Carnie M, Hanson C, Banta J, Symczak G, Robinson E, Schnipper J, Wong C, Weiss R (2019) Patient stakeholder engagement in research: a narrative review to describe foundational principles and best practice activities. *Health Expect* 22:307–316
- Manafa E, Petermann L, Mason-Lai P, Vandall-Walker V (2018) Patient engagement in Canada: a scoping review of the 'how' and 'what' of patient engagement in health research. *Health Res Policy Syst* 16:5
- Boivin A, L'Esperance A, Gauvin FP, Dumez V, Macaulay AC, Lehoux P, Abelson J (2018) Patient and public engagement in research and health system decision making: a systematic review of evaluation tools. *Health Expect* 21:1075–1084
- Forsythe L, Heckert A, Margolis MK, Schrandt S, Frank L (2018) Methods and impact of engagement in research, from theory to practice and back again: early findings from the patient-centered outcomes research institute. *Qual Life Res* 27:17–31
- Etchegary H, Linklater S, Duquette D, Wilkinson G, Francis V, Gionet E, Patey AM, Grimshaw JM (2023) "I think there has to be a mutual respect for there to be value": Evaluating patient engagement in a national clinical trial on de-implementation of low value care. *Res Involv Engagem* 9:70
- Stanski NL, Rodrigues CE, Strader M, Murray PT, Endre ZH, Bagshaw SM (2023) Precision management of acute kidney injury in the intensive care unit: current state of the art. *Intensive Care Med* 49:1049–1061
- Rodrigues CE, Endre ZH (2023) Definitions, phenotypes, and subphenotypes in acute kidney injury—moving towards precision medicine. *Nephrology (Carlton)* 28:83–96
- Thakar CV, Arrigain S, Worley S, Yared JP, Paganini EP (2005) A clinical score to predict acute renal failure after cardiac surgery. *J Am Soc Nephrol* 16:162–168
- Meersch M, Schmidt C, Hoffmeier A, Van Aken H, Wempe C, Gerss J, Zarbock A (2017) Prevention of cardiac surgery-associated AKI by implementing the KDIGO guidelines in high risk patients identified by biomarkers: the PrevAKI randomized controlled trial. *Intensive Care Med*. <https://doi.org/10.1007/s00134-016-4670-3>
- Knaus WA, Zimmerman JE, Wagner DP, Draper EA, Lawrence DE (1981) APACHE-acute physiology and chronic health evaluation: a physiologically based classification system. *Crit Care Med* 9:591–597
- Knaus WA, Wagner DP, Draper EA, Zimmerman JE, Bergner M, Bastos PG, Sirio CA, Murphy DJ, Lotring T, Damiano A et al (1991) The APACHE III prognostic system. risk prediction of hospital mortality for critically ill hospitalized adults. *Chest* 100:1619–1636
- Knaus WA, Draper EA, Wagner DP, Zimmerman JE (1985) APACHE II: a severity of disease classification system. *Crit Care Med* 13:818–829
- Englberger L, Suri RM, Li Z, Dearani JA, Park SJ, Sundt TM 3rd, Schaff HV (2010) Validation of clinical scores predicting severe acute kidney injury after cardiac surgery. *Am J Kidney Dis* 56:623–631
- Demirjian S, Bashour CA, Shaw A, Schold JD, Simon J, Anthony D, Soltesz E, Gadegebeku CA (2022) Predictive accuracy of a perioperative laboratory test-based prediction model for moderate to severe acute kidney injury after cardiac surgery. *JAMA* 327:956–964
- Flechet M, Falini S, Bonetti C, Güiza F, Schetz M, Van den Berghe G, Meyfroidt G (2019) Machine learning versus physicians' prediction of acute kidney injury in critically ill adults: a prospective evaluation of the AKIpredictor. *Crit Care* 23:282

25. Churpek MM, Carey KA, Edelson DP, Singh T, Astor BC, Gilbert ER, Winslow C, Shah N, Afshar M, Koyner JL (2020) Internal and external validation of a machine learning risk score for acute kidney injury. *JAMA Netw Open* 3:e2012892
26. Göcze I, Jauch D, Götz M, Kennedy P, Jung B, Zeman F, Gnewuch C, Graf BM, Gnann W, Banas B, Bein T, Schlitt HJ, Bergler T (2018) Biomarker-guided intervention to prevent acute kidney injury after major surgery: the prospective randomized BigPAK study. *Ann Surg* 267:1013–1020
27. Goldstein SL, Krallman KA, Schmerge A, Dill L, Gerhardt B, Chodaparavu P, Radomsky A, Kirby C, Askenazi DJ (2021) Urinary neutrophil gelatinase-associated lipocalin rules out nephrotoxic acute kidney injury in children. *Pediatr Nephrol* 36:1915–1921
28. Goldstein SL, Krallman KA, Roy JP, Collins M, Chima RS, Basu RK, Chawla L, Fei L (2023) Real-time acute kidney injury risk stratification-biomarker directed fluid management improves outcomes in critically ill children and young adults. *Kidney Int Rep* 8:2690–2700
29. Bellomo R, Forni LG, Busse LW, McCurdy MT, Ham KR, Boldt DW, Hästbacka J, Khanna AK, Albertson TE, Tumlin J, Storey K, Handisides D, Tidmarsh GF, Chawla LS, Ostermann M (2020) Renin and survival in patients given angiotensin ii for catecholamine-resistant vasodilatory shock. a clinical trial. *Am J Respir Crit Care Med* 202:1253–1261
30. Moledina DG, Obeid W, Smith RN, Rosales I, Sise ME, Moeckel G, Kashgarian M, Kuperman M, Campbell KN, Lefferts S, Meliambro K, Bitzer F, Perazella MA, Luciano RL, Pober JS, Cantley LG, Colvin RB, Wilson FP, Parikh CR (2023) Identification and validation of urinary CXCL9 as a biomarker for diagnosis of acute interstitial nephritis. *J Clin Invest*. <https://doi.org/10.1172/JCI168950>
31. Moledina DG, Wilson FP, Pober JS, Perazella MA, Singh N, Luciano RL, Obeid W, Lin H, Kuperman M, Moeckel GW, Kashgarian M, Cantley LG, Parikh CR (2019) Urine TNF- α and IL-9 for clinical diagnosis of acute interstitial nephritis. *JCI Insight*. <https://doi.org/10.1172/jci.insight.127456>
32. Billings FT IV, Shaw AD (2014) Clinical trial endpoints in acute kidney injury. *Nephron Clin Pract* 127:89–93
33. Leaf DE, Waikar SS (2017) End points for clinical trials in acute kidney injury. *Am J Kidney Dis* 69:108–116
34. Subbiah V (2023) The next generation of evidence-based medicine. *Nat Med* 29:49–58
35. KDIGO AKIw, (2012) Kidney Disease: Improving Global Outcomes (KDIGO) Clinical Practice Guideline for Acute Kidney Injury. *Kidney Int Suppl*: 1–138
36. Palevsky PM, Molitoris BA, Okusa MD, Levin A, Waikar SS, Wald R, Chertow GM, Murray PT, Parikh CR, Shaw AD, Go AS, Faubel SG, Kellum JA, Chinchilli VM, Liu KD, Cheung AK, Weisbord SD, Chawla LS, Kaufman JS, Devarajan P, Toto RM, Hsu CY, Greene T, Mehta RL, Stokes JB, Thompson AM, Thompson BT, Westenfelder CS, Tumlin JA, Warnock DG, Shah SV, Xie Y, Duggan EG, Kimmel PL, Star RA (2012) Design of clinical trials in acute kidney injury: report from an NIDDK workshop on trial methodology. *Clin J Am Soc Nephrol* 7:844–850
37. Shaw A (2011) Models of preventable disease: contrast-induced nephropathy and cardiac surgery-associated acute kidney injury. *Contrib Nephrol* 174:156–162
38. Zhang X, Zhang Y, Ye X, Guo X, Zhang T, He J, (2016) Overview of phase clinical trials for postmarket drug safety surveillance a status report from the ClinicalTrials.gov registry *BMJ open* 6(11) e010643
39. Nair D, Wilson FP (2019) Patient-reported outcome measures for adults with kidney disease: current measures, ongoing initiatives, and future opportunities for incorporation into patient-centered kidney care. *Am J Kidney Dis* 74:791–802
40. Weinfurt KP, Reeve BB (2022) Patient-reported outcome measures in clinical research. *JAMA* 328:472–473
41. Pocock SJ, Ariti CA, Collier TJ, Wang D (2012) The win ratio: a new approach to the analysis of composite endpoints in clinical trials based on clinical priorities. *Eur Heart J* 33:176–182
42. Kaddourah A, Basu RK, Bagshaw SM, Goldstein SL, Investigators A (2017) Epidemiology of acute kidney injury in critically ill children and young adults. *N Engl J Med* 376:11–20
43. Jetton JG, Boohaker LJ, Sethi SK, Wazir S, Rohatgi S, Soranno DE, Chishti AS, Woroniecki R, Mammen C, Swanson JR, Sridhar S, Wong CS, Kupferman JC, Griffin RL, Askenazi DJ, Neonatal Kidney C (2017) Incidence and outcomes of neonatal acute kidney injury (AWAKEN): a multicentre, multinational, observational cohort study. *Lancet Child Adolesc Health* 1:184–194
44. Klassen TP, Hartling L, Craig JC, Offringa M (2008) Children are not just small adults: the urgent need for high-quality trial evidence in children. *PLoS Med* 5:e172
45. Rocchi F, Tomasi P (2011) The development of medicines for children. part of a series on pediatric pharmacology, guest edited by gianvincenzo zuc-cotti, emilio clementi, and massimo molteni. *Pharmacol Res* 64:169–175
46. Sinha I, Jones L, Smyth RL, Williamson PR (2008) A systematic review of studies that aim to determine which outcomes to measure in clinical trials in children. *PLoS Med* 5:e96
47. BEST F, (2016) NBWG. FDA-NIH Biomarker Working Group. BEST (Biomarkers, EndpointS, and other tools) resource [internet]. 2016 FaDAU
48. Delanaye P, Ebert N, Melsom T, Gaspari F, Mariat C, Cavalier E, Björk J, Christensson A, Nyman U, Porrini E (2016) Iohexol plasma clearance for measuring glomerular filtration rate in clinical practice and research: a review. part 1: How to measure glomerular filtration rate with iohexol? *Clin Kidney J* 9:682–699
49. Desanti De Oliveira B, Xu K, Shen TH, Callahan M, Kiryluk K, D'Agati VD, Tatonetti NP, Barasch J, Devarajan P (2019) Molecular nephrology: types of acute tubular injury. *Nat Rev Nephrol* 15:599–612
50. Pallmann P, Bedding AW, Choodari-Oskoei B, Dimairo M, Flight L, Hampson LV, Holmes J, Mander AP, Odondi L, Sydes MR, Villar SS, Wason JMS, Weir CJ, Wheeler GM, Yap C, Jaki T (2018) Adaptive designs in clinical trials: why use them, and how to run and report them. *BMC Med* 16:29
51. Kaas-Hansen BS, Granholm A, Anthon CT, Kjaer MN, Sivapalan P, Maa-gaard M, Schjorring OL, Fagerberg SK, Ellekjaer KL, Molgaard J, Ekstrom CT, Moller MH, Perner A (2022) Causal inference for planning randomised critical care trials: protocol for a scoping review. *Acta Anaesthesiol Scand* 66:1274–1278
52. Pickkers P, Mehta RL, Murray PT, Joannidis M, Molitoris BA, Kellum JA, Bachler M, Hoste EAJ, Hoiting O, Krell K, Ostermann M, Rozendaal W, Valkonen M, Brealey D, Beishuizen A, Meziani F, Murugan R, de Geus H, Payen D, van den Berg E, Arend J, Investigators S-A (2018) Effect of human recombinant alkaline phosphatase on 7-day creatinine clearance in patients with sepsis-associated acute kidney injury: a randomized clinical trial. *JAMA* 320:1998–2009
53. James MT, Pannu N, Hemmelgarn BR, Austin PC, Tan Z, McArthur E, Manns BJ, Tonelli M, Wald R, Quinn RR, Ravani P, Garg AX (2017) Derivation and external validation of prediction models for advanced chronic kidney disease following acute kidney injury. *JAMA* 318:1787–1797
54. Wilson TA, de Koning L, Quinn RR, Zarke KB, McArthur E, Iskander C, Roshanov PS, Garg AX, Hemmelgarn BR, Pannu N, James MT (2021) Derivation and external validation of a risk index for predicting acute kidney injury requiring kidney replacement therapy after noncardiac surgery. *JAMA Netw Open* 4:e2121901
55. Eldridge SM, Lancaster GA, Campbell MJ, Thabane L, Hopewell S, Coleman CL, Bond CM (2016) Defining feasibility and pilot studies in preparation for randomised controlled trials: development of a conceptual framework. *PLoS ONE* 11:e0150205
56. Granholm A, Alhazzani W, Derde LPG, Angus DC, Zampieri FG, Hammond NE, Sweeney RM, Myatra SN, Azoulay E, Rowan K, Young PJ, Perner A, Moller MH (2022) Randomised clinical trials in critical care: past, present and future. *Intensive Care Med* 48:164–178
57. Files DC, Matthay MA, Calfee CS, Aggarwal NR, Asare AL, Beitler JR, Berger PA, Burnham EL, Cimino G, Coleman MH, Crippa A, Discacciati A, Gandotra S, Gibbs KW, Henderson PT, Ittner CAG, Jauregui A, Khan KT, Koff JL, Lang J, LaRose M, Levitt J, Lu R, McKeenan JD, Meyer NJ, Russell DW, Thomas KW, Eklund M, Esserman LJ, Liu KD, Network ICAPT, undefined, (2022) I-SPY COVID adaptive platform trial for COVID-19 acute respiratory failure: rationale, design and operations. *BMJ Open* 12:e060664
58. Australian Pfif, New Zealand Intensive Care Society Clinical Trials Group AHSCCSCN, the Irish Critical Care Trials G, Young PJ, Bagshaw SM, Forbes AB, Nichol AD, Wright SE, Bailey M, Bellomo R, Beasley R, Brickell K, Eastwood GM, Gattas DJ, van Haren F, Litton E, Mackle DM, McArthur CJ, McGuinness SP, Mouncey PR, Navarra L, Opgenorth D, Pilcher D, Saxena MK, Webb SA, Wiley D, Rowan KM (2020) Effect of stress ulcer prophylaxis with proton pump inhibitors vs histamine-2 receptor blockers on in-hospital mortality among icu patients receiving invasive mechanical ventilation: the peptic randomized clinical trial. *JAMA* 323:616–626
59. Zarbock A, Forni LG, Ostermann M, Ronco C, Bagshaw SM, Mehta RL, Bellomo R, Kellum JA (2023) Designing acute kidney injury clinical trials. *Nat Rev Nephrol* 20(2):137–146

-
60. Granholm A, Kaas-Hansen BS, Lange T, Munch MW, Harhay MO, Zampieri FG, Perner A, Moller MH, Jensen AKG (2023) Use of days alive without life support and similar count outcomes in randomised clinical trials - an overview and comparison of methodological choices and analysis methods. *BMC Med Res Methodol* 23:139
 61. Auriemma CL, Taylor SP, Harhay MO, Courtright KR, Halpern SD (2021) Hospital-free days: a pragmatic and patient-centered outcome for trials among critically and seriously ill patients. *Am J Respir Crit Care Med* 204:902–909
 62. Martin GL, Atramont A, Mazars M, Tajahmady A, Agamaliyev E, Singer M, Leone M, Legrand M (2023) Days spent at home and mortality after critical illness: a cluster analysis using nationwide data. *Chest* 163:826–842
 63. Zampieri FG, Damiani LP, Biondi RS, Freitas FGR, Veiga VC, Figueiredo RC, Serpa-Neto A, Manoel ALO, Miranda TA, Correa TD, Azevedo LCP, Silva NB, Machado FR, Cavalcanti AB, Bricnet, (2022) Hierarchical endpoint analysis using win ratio in critical care: an exploration using the balanced solutions in intensive care study (BaSICS). *J Crit Care* 71:154113
 64. Heerspink HL, Jongs N, Schloemer P, Little DJ, Brinker M, Tasto C, Karpofors M, Wheeler DC, Bakris G, Perkovic V, Nkulikiyinka R, Rossert J, Gasparyan SB (2023) Development and validation of a new hierarchical composite end point for clinical trials of kidney disease progression. *J Am Soc Nephrol*. <https://doi.org/10.1681/ASN.0000000000000243>
 65. Redfors B, Gregson J, Crowley A, McAndrew T, Ben-Yehuda O, Stone GW, Pocock SJ (2020) The win ratio approach for composite endpoints: practical guidance based on previous experience. *Eur Heart J* 41:4391–4399
 66. Ajufo E, Nayak A, Mehra MR (2023) Fallacies of using the win ratio in cardiovascular trials: challenges and solutions. *JACC Basic Transl Sci* 8:720–727
 67. Zampieri FG, Damiani LP, Bagshaw SM, Semler MW, Churpek M, Azevedo LCP, Figueiredo RC, Veiga VC, Biondi R, Freitas FR, Machado FR, CavalcantiBricnet AB (2023) Conditional treatment effect analysis of two infusion rates for fluid challenges in critically ill patients: a secondary analysis of balanced solution versus saline in intensive care study (BaSICS) trial. *Ann Am Thorac Soc* 20:872–879
 68. Fountzilias E, Tsimberidou AM, Vo HH, Kurzrock R (2022) Clinical trial design in the era of precision medicine. *Genome Med* 14:101
 69. Lazzareschi D, Mehta RL, Dember LM, Bernholz J, Turan A, Sharma A, Kheterpal S, Parikh CR, Ali O, Schulman IH, Ryan A, Feng J, Simon N, Pirracchio R, Rossignol P, Legrand M (2023) Overcoming barriers in the design and implementation of clinical trials for acute kidney injury: a report from the 2020 kidney disease clinical trialists meeting. *Nephrol Dial Transplant* 38:834–844
 70. Legrand M, Bagshaw SM, Koyner JL, Schulman IH, Mathis MR, Bernholz J, Coca S, Gallagher M, Gaudry S, Liu KD, Mehta RL, Pirracchio R, Ryan A, Steubl D, Stockbridge N, Erlandsson F, Turan A, Wilson FP, Zarbock A, Bokoch MP, Casey JD, Rossignol P, Harhay MO (2022) Optimizing the design and analysis of future AKI trials. *J Am Soc Nephrol* 33:1459–1470
 71. Hobbs BP, Pestana RC, Zabor EC, Kaizer AM, Hong DS (2022) Basket trials: review of current practice and innovations for future trials. *J Clin Oncol* 40:3520–3528
 72. Tallarico RT, Neto AS, Legrand M (2022) Pragmatic platform trials to improve the outcome of patients with acute kidney injury. *Curr Opin Crit Care* 28:622–629
 73. Loudon K, Zwarenstein M, Sullivan F, Donnan P, Treweek S (2013) Making clinical trials more relevant: improving and validating the PRECIS tool for matching trial design decisions to trial purpose. *Trials* 14:115